BD (NYSE: BDX) shares dipped slightly before hours today on fourth-quarter results that came in mixed compared to the consensus forecast.
Shares of BD fell 1.4% to $173.90 apiece in pre-market trading today.
The Franklin Lakes, New Jersey-based medtech giant reported profits of $493 million. That equals $1.72 per share on sales of $5.89 billion for the three months ended Sept. 30, 2025.
BD — one of the largest medical device companies in the world — recorded a 23.2% bottom-line gain on a sales increase of 8.3%.
Adjusted to exclude one-time items, earnings per share came in at $3.96. That landed 5¢ ahead of expectations on Wall Street. However, sales fell just shy of estimates, as experts projected $5.91 billion in revenue.
The company reported revenue growth across all three of its business segments. With more than $3.15 billion in sales, BD Medical saw 11.2% year-over-year growth from the same three-month period a year ago. Life Sciences grew 2.1% to nearly $1.4 billion and Interventional saw an 8.5% uptick to nearly $1.4 billion as well.
Medical’s growth was attributed to Vascular Access Management, partially offset by volume-based procurement in China. The company also reported a record quarter for Alaris capital installations. China procurement also partially offset some business in Interventional, although the company reported double-digit growth in Advanced Tissue Regeneration and Biosurgery, and high single-digit growth in Infection Prevention, partially offset by legacy U.S. hernia.
BD expects 2026 revenue growth in the “low single-digit-plus” range. It forecasts adjusted EPS between $14.75 and $15.05.
“Our resilient business model and commitment to commercial and operational execution enabled us to deliver 3.9% organic growth in New BD along with substantial adjusted margin and earnings growth in fiscal 2025,” said Tom Polen, chair, CEO and president of BD. “We remain on track to complete the combination of BD’s Biosciences and Diagnostic Solutions business with Waters Corporation around the end of the first quarter of calendar year 2026. New BD will be a leading Med Tech company making a profound impact on health care and patients worldwide. By focusing on growth in attractive markets and executing BD Excellence, we are driving stronger margins, earnings expansion and long-term value.”
